crystallization communications
Expression, crystallization and preliminary crystallographic study of the C-terminal half of nsp2 from SARS coronavirus
aNational Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, People's Republic of China, bGraduate University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China, cStructural Biology Laboratory, Tsinghua University, Beijing 100084, People's Republic of China, and dCollege of Life Sciences and Tianjin State Laboratory of Protein Science, Nankai University, Tianjin 300071, People's Republic of China
*Correspondence e-mail: lixm@sun5.ibp.ac.cn
SARS coronavirus (SARS-CoV) is the aetiological agent of the highly infectious severe acute respiratory syndrome (SARS). To gain a better understanding of SARS-CoV replication and transcription proteins, a preliminary X-ray crystallographic study of the C-terminal domain of SARS-CoV nonstructural protein 2 (nsp2) is reported here. The C-terminal domain of SARS-CoV nsp2 was cloned, overexpressed, purified and crystallized using polyethylene glycol 5000 monomethyl ether as the precipitant; the crystals diffracted to 2.5 Å resolution. The crystals belonged to P65, with unit-cell parameters a = b = 112.8, c = 91.1 Å, α = β = 90, γ = 120°. One molecule is assumed to be present per which gives a Matthews coefficient of 2.89 Å3 Da−1 and a solvent content of 56.2%.
Keywords: severe acute respiratory syndrome; SARS-CoV; nonstructural protein 2; nsp2.
1. Introduction
The 16 replicase/transcriptase proteins are crucial for the life cycle of SARS coronavirus (SARS-CoV), which is the causative agent of the highly infectious severe acute respiratory syndrome (SARS) that first appeared in late 2002 (Stadler et al., 2003) in Asia and subsequently spread worldwide. SARS-CoV belongs to the Coronaviridae family, with a single positive-stranded RNA genome of approximately 30 kb in length (Snijder et al., 2003).
Since the SARS pandemic, the three-dimensional structures and functions of most of the replicase/transcriptase components, the nonstructural proteins (nsps), of SARS-CoV have been determined (Zhang et al., 2010; Yang et al., 2003; Almeida et al., 2006; Su et al., 2006; Xue et al., 2008; Xu et al., 2009). However, the structure and function of nsp2 from either SARS-CoV or related coronaviruses have remained uncharacterized. To date, the only reported of a coronavirus nsp2 is that of the N-terminal domain of nsp2 from avian infectious bronchitis virus (IBV; Yang et al., 2009), a representive of the group 3 coronaviruses which is quite different from SARS-CoV nsp2 in primary sequence (with a sequence identity of less than 20%) and gene locus (with no nsp1 prior to nsp2 in IBV). Meanwhile, owing to a lack of research on nsp2-deficient viruses in animal models or on changes in host environment resulting from nsp2 deficiency, it has been widely accepted that nsp2 replicase proteins are dispensable for replication of mouse hepatitis virus (MHV) and SARS-CoV in cell culture owing to the detection of genomic and subgenomic RNA production of nsp2-deficient viruses in cell culture (Graham et al., 2005).
In order to help to elucidate the function(s) of this relatively large protein (70 and 65 kDa for SARS-CoV and MHV, respectively), we now report the expression, purification and crystallization of the C-terminal half of nsp2 from SARS-CoV (referred to here as nsp2C; 58 kDa, corresponding to Lys112–Gly638 of full-length SARS-CoV nsp2) as well as its preliminary
by single-wavelength (SAD). Further analysis of the structure and function of nsp2 from SARS-CoV and other members of the coronavirus family should allow the elucidation of its precise function(s) involved in coronavirus pathogenesis on the basis of our of SARS-CoV nsp2C.2. Materials and methods
2.1. Cloning and expression
The coding sequence for SARS-CoV nsp2C was amplified by a standard PCR-based approach from the cDNA of SARS-CoV BJ01 strain (corresponding to Lys292–Gly818 of pp1a replicative polyprotein, renumbered as Lys112–Gly638). The PCR product was digested by BamHI and NotI and ligated into a pGEX-6p-1 expression vector (Pharmacia, New York, USA). The integrity of the construct was confirmed by DNA sequencing. SARS-CoV nsp2C was overexpressed in Escherichia coli strain BL21 (DE3) (Novagen, Merck, USA) as a GST (glutathione S-transferase) fusion protein. A selenomethionyl (SeMet) derivative of nsp2C was prepared using the method of methionine-biosynthesis pathway inhibition. Expression of native and SeMet-derivative nsp2C was performed in 0.8 l Luria–Bertani medium and M9 medium, respectively, which was incubated at 310 K until the OD600 reached about 0.6. SARS-CoV nsp2C expression was induced by the addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for an additional 16 h at 289 K. For the preparation of soluble protein fractions, cells from the 0.8 l culture were pelleted, resuspended in 50 ml cold PBS as a lysis buffer containing 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, 1 mM DTT, 1 mM EDTA and 0.01% NP-40 pH 8.5 and lysed using a JN-3000 PLUS low-temperature ultrahigh-pressure cell disrupter (JNBIO, Guangzhou, People's Republic of China).
2.2. Purification
The supernatant after centrifugation was collected and the fusion protein was purified by GST-glutathione M NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, 10% glycerol pH 8.5), leaving five additional residues (GPLGS) at the N-terminus. SARS-CoV nsp2C was further purified by Resource Q ion-exchange (Amersham Biosciences, USA) at 291 K in 25 mM Tris–HCl, 1 mM EDTA, 1 mM DTT, 0.01% NP-40 pH 8.5 with a 50–250 mM NaCl gradient and achieved high the protein purity was estimated to be about 90% by inspection of Coomassie-stained Tris–glycine SDS–PAGE gels (Fig. 1). All proteins were further characterized by MALDI–TOF and incorporation of selenomethionine was also confirmed by Fractions containing pure protein were pooled and concentrated to 8 mg ml−1 for crystallization.
The native and SeMet-derivative nsp2C-GST fusion proteins were further purified using the same procedure as follows: briefly, the bacterial cell lysate containing nsp2C protein was incubated with Glutathione-Sepharose 4B resin (GE Healthcare, USA) at 277 K. The GST tag was removed by overnight digestion at 277 K using GST-tagged PreScission protease (Amersham Biosciences) in 1×PBS (137 m2.3. Crystal growth, data collection and processing
Initial crystals were obtained via the hanging-drop vapour-diffusion method at 291 K by mixing 1 µl protein solution and 1 µl reservoir solution. Initial needle-shaped crystals of SARS-CoV nsp2C with extensive appeared after one week in a condition from Hampton Research Crystal Screen. Crystals suitable for data collection with a length of up to 200 µm and variable thickness were grown using a reservoir solution consisting of 0.1 M Bis-Tris pH 6.5, 0.2 M NaCl, 20%(w/v) polyethylene glycol 5000 monomethyl ether (Fig. 2a). Crystals of the SeMet derivative of nsp2C were obtained using the same conditions but grew to larger size (Fig. 2b). Prior to data collection, the crystals were dehydrated for 2 h with reservoir solution plus 10% glycerol and were immediately soaked in cryoprotectant solution constituted of reservoir solution with 20% ethylene glycol followed by flash-freezing in liquid nitrogen.
The crystal-to-detector distance was set to 273.5 and 362.5 mm for native and SeMet-derivative nsp2C, respectively. All frames were collected at 93 K using a 0.8° oscillation angle with an exposure time of 2 s per frame. A total of 300 frames and 450 frames were collected for native and SeMet nsp2C, respectively. A native data set for nsp2C was collected to 2.7 Å resolution at a wavelength of 1.0 Å using a MAR 165 CCD detector on beamline BL17U at Shanghai Synchrotron Radiation Facility (SSRF; People's Republic of China) and a single-wavelength ) data set for the SeMet derivative of nsp2C was collected to 3.5 Å resolution (Fig. 3) at a wavelength of 0.9787 Å using an ADSC Q270 CCD detector on beamline BL17A at Photon Factory (PF; Tsukuba, Japan). Data were processed, integrated and scaled using the HKL-2000 program package (Otwinowski & Minor, 1997). The initial phases were obtained using SHELX (Sheldrick, 2008) and PHENIX (Adams et al., 2002). The selenomethionine sites were located and interpretable maps were obtained. The phases were greatly improved after density-modification procedures using RESOLVE (Terwilliger, 2000, 2001) and DM in CCP4 (Winn et al., 2011). A summary of data collection and processing is shown in Table 1.
(SAD; Terwilliger & Berendzen, 1999
|
3. Results and discussion
The crystal of nsp2C belonged to P65, which was identified after we had obtained the initial phases using SHELX and the SeMet-nsp2C data set. The unit-cell parameters were a = b = 112.8, c = 91.1 Å, α = β = 90, γ = 120° and there was only one molecule per corresponding to a calculated Matthews coefficient of 2.89 Å3 Da−1 and a solvent content of 57.4% (Matthews, 1968). The anomalous data provided four clear selenium sites. The initial phases were improved by solvent flattening (DM; Winn et al., 2011) and the electron-density map allowed us to trace most of the main-chain residues of SARS-CoV nsp2C. After several iterations of density modification using both the DM and SHARP programs, the phases were greatly improved, with most of the amino-acid residues being clearly interpretable (Fig. 4); exceptions were the C-terminal end, which consists mostly of loop and coil, as well as electron density in some regions owing to flexibility. Further model building and of the structure of SARS-CoV nsp2C is in progress. The successful crystallization of nsp2C from SARS-CoV to give crystals that were suitable for should allow us to answer many of the fundamental questions that remain unclear about the role(s) of nsp2 in the regulation of coronavirus pathogenesis.
Acknowledgements
This work was supported by the Ministry of Science and Technology 973 Project (grant Nos. 2006CB806503 and 2007CB914301) and the National Natural Science Foundation of China (grant Nos. 30221003 and 30730022).
References
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K. & Terwilliger, T. C. (2002). Acta Cryst. D58, 1948–1954. Web of Science CrossRef CAS IUCr Journals Google Scholar
Almeida, M. S., Johnson, M. A. & Wüthrich, K. (2006). J. Biomol. NMR, 36, Suppl. 1, 46. Google Scholar
Graham, R. L., Sims, A. C., Brockway, S. M., Baric, R. S. & Denison, M. R. (2005). J. Virol. 79, 13399–13411. Web of Science CrossRef PubMed CAS Google Scholar
Matthews, B. W. (1968). J. Mol. Biol. 33, 491–497. CrossRef CAS PubMed Web of Science Google Scholar
Otwinowski, Z. & Minor, W. (1997). Methods Enzymol. 276, 307–326. CrossRef CAS Web of Science Google Scholar
Sheldrick, G. M. (2008). Acta Cryst. A64, 112–122. Web of Science CrossRef CAS IUCr Journals Google Scholar
Snijder, E. J., Bredenbeek, P. J., Dobbe, J. C., Thiel, V., Ziebuhr, J., Poon, L. L., Guan, Y., Rozanov, M., Spaan, W. J. & Gorbalenya, A. E. (2003). J. Mol. Biol. 331, 991–1004. Web of Science CrossRef PubMed CAS Google Scholar
Stadler, K., Masignani, V., Eickmann, M., Becker, S., Abrignani, S., Klenk, H. D. & Rappuoli, R. (2003). Nature Rev. Microbiol. 1, 209–218. CrossRef CAS Google Scholar
Su, D., Lou, Z., Sun, F., Zhai, Y., Yang, H., Zhang, R., Joachimiak, A., Zhang, X. C., Bartlam, M. & Rao, Z. (2006). J. Virol. 80, 7902–7908. Web of Science CrossRef PubMed CAS Google Scholar
Terwilliger, T. C. (2000). Acta Cryst. D56, 965–972. Web of Science CrossRef CAS IUCr Journals Google Scholar
Terwilliger, T. C. (2001). Acta Cryst. D57, 1763–1775. Web of Science CrossRef CAS IUCr Journals Google Scholar
Terwilliger, T. C. & Berendzen, J. (1999). Acta Cryst. D55, 849–861. Web of Science CrossRef CAS IUCr Journals Google Scholar
Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242. Web of Science CrossRef CAS IUCr Journals Google Scholar
Xu, Y., Cong, L., Chen, C., Wei, L., Zhao, Q., Xu, X., Ma, Y., Bartlam, M. & Rao, Z. (2009). J. Virol. 83, 1083–1092. Web of Science CrossRef PubMed CAS Google Scholar
Xue, X., Yu, H., Yang, H., Xue, F., Wu, Z., Shen, W., Li, J., Zhou, Z., Ding, Y., Zhao, Q., Zhang, X. C., Liao, M., Bartlam, M. & Rao, Z. (2008). J. Virol. 82, 2515–2527. Web of Science CrossRef PubMed CAS Google Scholar
Yang, A., Wei, L., Zhao, W., Xu, Y. & Rao, Z. (2009). Acta Cryst. F65, 788–790. Web of Science CrossRef IUCr Journals Google Scholar
Yang, H., Yang, M., Ding, Y., Liu, Y., Lou, Z., Zhou, Z., Sun, L., Mo, L., Ye, S., Pang, H., Gao, G. F., Anand, K., Bartlam, M., Hilgenfeld, R. & Rao, Z. (2003). Proc. Natl Acad. Sci. USA, 100, 13190–13195. Web of Science CrossRef PubMed CAS Google Scholar
Zhang, S., Zhong, N., Xue, F., Kang, X., Ren, X., Chen, J., Jin, C., Lou, Z. & Xia, B. (2010). Protein Cell, 1, 371–383. Web of Science CrossRef CAS PubMed Google Scholar
© International Union of Crystallography. Prior permission is not required to reproduce short quotations, tables and figures from this article, provided the original authors and source are cited. For more information, click here.